Latest Breaking News On - Inhibrx inc - Page 1 : comparemela.com

Insider Selling: Inhibrx, Inc. (NASDAQ:INBX) Insider Sells 300,000 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) insider Brendan P. Eckelman sold 300,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.30, for a total value of $10,290,000.00. Following the sale, the insider now directly owns 1,735,553 shares of the company’s stock, […]

Sanofi: Sanofi completes acquisition of Inhibrx, Inc.

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Set for Significant Growth

The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD.